Conditions: Overactive Bladder
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 322
Healthy volunteers: no

Brief summary:
This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy.

Detailed description:

Arms:
arm 1: Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks. arm 2: Placebo once daily on an empty stomach for 14 weeks.

Interventions: intervention 1: trospium chloride intervention 2: placebo
Intervention descriptions: intervention 1: Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks intervention 2: Placebo once daily on an empty stomach for 14 weeks.

Protocol document: